There are individual treatment pathways for patients with a category A and class B CPS and for patients with a class C CPS. Additionally, the authors deliver an algorithmic method of these agents within the transplant inhabitants, focusing on initial line use of glucagon-like peptide one (GLP-1) agonists due to their extra Advantages in glucose man